510 research outputs found
Ryhiner-Kartensammlung / 55 L' Europe : dressée sur les observations de M.rs de l'Academie royale des sciences et quelques autres; & sur les memoires les plus recens
No full textpar G. De l'Isle geographe ; H. van Loon sculpc. ; [Titelkartusche:] C. Simonneau inv. et fec."Avec privilege du roy pour 20 ans"Erläuterungen ("Avertissement") oben link
Ryhiner-Kartensammlung / 39 L' Espagne : dressée sur la description qui en a été faite par Rodrigo Mendez Sylva et sur plusieurs relations et cartes manuscrites ou imprimées de ce royaume., rectifiées par les observations de M.rs de l'Academie des Sciences & autres astronomes
No full textpar G. de l'Isle geographe ; Berey sculpsit ; [Kartuschenstecher:] Car. Simonneau inv. et sculp."Avec privilege du roy pour 20 ans
Ryhiner-Kartensammlung / 28 Carte des provinces unies des Pays Bas : tirée des cartes les plus correctes qui en ont eté faites sur les lieux rectifiée par les observations et operations geometriques de Snellius et par celles que Mr. Cassini y a faites en dernier lieu
No full textpar G. de l'Isle geographe de l'Academie royale des sciences ; gravée par Lièbaux le fils ; [Kartusche:] C. Simonneau"Avec privilege du roy pour 20 ans
Ryhiner-Kartensammlung / 21 L' Italie : dressée sur les observations de M.rs de l'Académie royale des sciences sur celles du R.P. Riccioli de la compagnie de Jesus, et autres astronomes du pays, et sur plusieurs autres mémoires
No full textpar G. De l'Isle géographe ; Ph. Buache p.g.d.r. d l'A.r.d.s. gendre de l'auteur ; gravé par Berey ; [Titelkartusche:] L. Simonneau inv. et fecit"Avec privilege du roy
Clinical worsening in trials of pulmonary arterial hypertension: results and implications.
No full textPurpose of review: Time to clinical worsening (TTCW) can be used to assess disease progression associated with pulmonary arterial hypertension (PAH). As a consequence, it is highly relevant to patients, clinicians, and regulatory agencies. The majority of clinical trials of PAH-specific drug therapies have included TTCW as a secondary endpoint; this article summarizes the results of randomized controlled clinical trials in PAH, specifically with respect to the clinical worsening endpoint. Recent findings: Some trials have demonstrated a treatment-related delay in TTCW and others have not. Recent results suggest that TTCW shows particular promise in detecting disease progression, even in mildly affected patients. Definitions of clinical worsening have also varied across clinical trials; although all have agreed on the inclusion of all-cause death and hospitalization due to PAH in the definition, the inclusion of additional parameters defining 'disease progression' has differed. Summary: There is a need for a clear and uniform definition of TTCW that can be tailored to the study population being investigated; the endpoint may require adaptation for patients in different functional classes and with different causes. Consistency of event reporting within a trial may be improved by employing a committee to adjudicate events. Trials are beginning to include TTCW as a primary endpoint; the results will be important in establishing the validity of whether this parameter should become the endpoint of choice in PAH trials in the futur
An overview of the 6th World Symposium on Pulmonary Hypertension
No full textState of the art summary on diagnosis, prognosis, therapy and future perspectives of pulmonary hypertensio
- …
